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Abstract
Proteasome inhibitors (PIs), namely bortezomib, have become a cornerstone therapy for multiple
myeloma (MM), potently reducing tumor burden and inhibiting pathologic bone destruction. In
clinical trials, carfilzomib, a next generation epoxyketone-based irreversible PI, has exhibited
potent anti-myeloma efficacy and decreased side effects compared with bortezomib. Carfilzomib
and its orally bioavailable analog oprozomib, effectively decreased MM cell viability following
continual or transient treatment mimicking in vivo pharmacokinetics. Interactions between
myeloma cells and the bone marrow (BM) microenvironment augment the number and activity of
bone-resorbing osteoclasts (OCs) while inhibiting bone-forming osteoblasts (OBs), resulting in
increased tumor growth and osteolytic lesions. At clinically relevant concentrations, carfilzomib
and oprozomib directly inhibited OC formation and bone resorption in vitro, while enhancing
osteogenic differentiation and matrix mineralization. Accordingly, carfilzomib and oprozomib
increased trabecular bone volume, decreased bone resorption and enhanced bone formation in
non-tumor bearing mice. Finally, in mouse models of disseminated MM, the epoxyketone-based
PIs decreased murine 5TGM1 and human RPMI-8226 tumor burden and prevented bone loss.
These data demonstrate that, in addition to anti-myeloma properties, carfilzomib and oprozomib
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effectively shift the bone microenvironment from a catabolic to an anabolic state and, similar to
bortezomib, may decrease skeletal complications of MM.
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INTRODUCTION
Multiple myeloma (MM), a malignancy of plasma cells that reside within the bone marrow
(BM), is associated with the development of osteolytic lesions (70–80% of patients)
characterized by increased osteoclast (OC) numbers and resorption and suppressed
osteoblast (OB) differentiation and bone formation. The interaction of myeloma cells with
stromal and osteoprogenitor cells in the BM leads to the overexpression of multiple OC
activating factors including RANKL, MIP1-α, interleukin (IL)-3, osteopontin, IL-6 and
vascular endothelial growth factor.1,2 In turn, OCs also support myeloma proliferation and
survival by production of growth factors such as IL-6, osteopontin, BAFF and APRIL.1
Conversely, OB formation and activity is significantly reduced by tumoral production of OB
inhibitory factors such as DKK-1, sFRP-2, sFRP-3, IL-7 and IL-3, and by direct myeloma
and OB cell-to-cell interactions.3
The first generation proteasome inhibitor (PI) bortezomib has proven highly efficacious in
treating MM, with greatly improved response rates and overall survival in both newly
diagnosed and relapsed/refractory myeloma patients.4,5 Bortezomib, a dipeptide boronic
acid,6 primarily inhibits the chymotrypsin-like activity of the 20S proteasome with slowly
reversible binding kinetics.7 The therapeutic success of bortezomib relies on pleiotropic
effects, which decrease both the growth and survival of myeloma cells and the interactions
between myeloma cells and the BM microenvironment (reviewed in Hideshima and
Anderson8). Bortezomib treatment has been associated with clinically beneficial effects on
myeloma bone disease,9 with reports of increase in bone formation markers and decrease in
markers of bone resorption (reviewed in Trepos et al.10). This effect of bortezomib on bone
remodeling is not only the consequence of reduced tumor burden, but also due to direct
effects on bone cells with the promotion of osteoblastogenesis and reduction of OC numbers
reported in both myelomatous and non-myelomatous in vivo models11,12 as well as in
numerous in vitro studies.13–18
Although results obtained with bortezomib are encouraging, a substantial proportion of
myeloma patients are refractory to this agent or develop drug resistance.19 Peripheral
neuropathy is a major and dose-limiting adverse effect of bortezomib treatment,19,20
prompting the development of next-generation PIs with safer toxicity profiles, better tissue
distribution and/or oral bioavailability. Within these new PIs, carfilzomib and oprozomib
(both from Onyx Pharmaceuticals, San Francisco, CA, USA) are peptide epoxyketones6
with selective and irreversible binding to the proteasome chymotrypsin-like subunit.7 In
preclinical studies, carfilzomib exhibits anti-myeloma activity with IC50 values and
pleiotropic cellular effects comparable to those of bortezomib.21–23 Furthermore,
carfilzomib has been reported to overcome acquired resistance to bortezomib, melphalan
and dexamethasone.21 Phase II and III studies are ongoing in patients with relapsed or
refractory myeloma with no serious adverse reports of peripheral neuropathy.24,25
Oprozomib (formerly known as ONX 0912 and PR-047) is an orally bioavailable analog of
carfilzomib, which has been reported to have anti-tumor activity equivalent to carfilzomib in
xenograft models of non-Hodgkin’s lymphoma and colorectal cancer,26 and also to exert
anti-MM activity in vitro and in myeloma animal models.27 Its favorable pharmacologic
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profile and tolerability supports its further clinical development and Phase I clinical trials are
underway.28
While epoxyketone-based PIs have been shown to stimulate bone formation29 and inhibit
osteoclastogenesis,30 the specific bone effects of carfilzomib and oprozomib are unknown.
In this report, we show that both compounds promote OB differentiation and function and
inhibit OC formation and resorption equivalently to bortezomib in vitro and in vivo. Both
drugs were effective at reducing myeloma burden and osteolytic bone destruction in mice
bearing BM-disseminated myeloma. Collectively, our data demonstrate that carfilzomib and
oprozomib effectively inhibit myeloma growth and shift the bone microenvironment from a
catabolic to an anabolic state, with reduced toxicity24,28 and oral administration (in the case
of oprozomib)26,27 being significant advantages to patients.
MATERIALS AND METHODS
Animals
C57Bl/6 and NOD.SCID.IL2Rγ−/− mice were obtained from The Jackson Laboratory (Bar
Harbor, ME, USA). C57Bl/KaLwRij mice were obtained from Dr G Mundy (Vanderbilt
University, Nashville, TN, USA). All mice were bred in-house under specific pathogen-free
conditions according to guidelines of the Washington University Division of Comparative
Medicine. The Animal Ethics Committee approved all experiments.
Drugs
Bortezomib was purchased from Selleckem (Houston, TX, USA). Carfilzomib and
oprozomib were supplied by Onyx Pharmaceuticals.
Cell lines
Human myeloma cell lines were obtained from the American Type Culture Collection or
other origins31 and modified to express firefly luciferase. The 5TGM1-GFP murine
myeloma line was obtained from Dr G Mundy.32
Viability assays
A total of 5 × 104 cells/ml were plated and standard MTT assay (Sigma-Aldrich, St Louis,
MO, USA) was performed. For transient dosing experiments, cells were washed twice with
phosphate-buffered saline and replaced with drug-free media after 1 h (bortezomib,
carfilzomib) or 4 h (oprozomib).
MM.1S-luc co-cultures
Primary human CD138-negative BM stromal cells (BMSCs) from MM patients were plated
at 1 × 104 cells/well in 96-well plates for 24 h, serum-starved for 12 h and then MM.1 S-luc
cells (1 × 105 cells per well) were added and co-cultured for an additional 48 h. Pre-OCs
were generated under osteoclastogenic conditions and 4 × 103 MM.1S-luc cells per well
were added, with co-cultures maintained in medium supplemented with 0.5% fetal bovine
serum for 5 days. MM.1S-luc viability was assessed by luciferase activity.
In vitro OC differentiation and resorption
Peripheral blood mononuclear cells (PBMCs) from healthy donors were differentiated as in
Garcia-Gomez et al.33 Briefly, adherent cells were maintained in osteoclastogenic medium
(50 ng/ml RANKL and 25 ng/ml M-CSF (Peprotech, London, UK) for 14 days (pre-OCs) or
21 days (mature OCs). TRAP + (Sigma-Aldrich) multinucleated (≥3 nuclei) OCs were
enumerated. To measure resorption, PBMCs were seeded on calcium-coated wells (BD
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Biosciences, Bedford, MA, USA) in osteoclastogenic medium for 17 days (with 1 μM
dexamethasone the first week), and resorption pit area was calculated.
Nuclear factor-κB (NF-κB) translocation and actin ring formation
Pre-OCs received a 3 h pulse of PIs followed by stimulation with 50 ng/ml RANKL for 30
min. Cells were fixed in 4% paraformaldehyde, permeabilized with 0.1% Triton X-100, and
incubated with a mouse anti-p65 antibody (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) and a secondary rhodamine-conjugated antibody. Pre-OC F-actin microfilaments were
stained using rhodamine-conjugated phalloidin (Invitrogen, Carlsbad, CA, USA).
In vitro OB differentiation, alkaline phosphatase (ALP) activity and mineralization
Primary mesenchymal stem cells (MSCs) from BM aspirates of healthy donors (n =6) and
MM patients with (n =6) or without osteolytic bone lesions (n =3) were generated and
assayed as described.33 The human MSC line (hMSC-TERT) was a generous gift from Dr D
Campana (St Jude Children’s Research Hospital, Memphis, TN, USA). Briefly, the hMSC-
TERT and primary MSCs (passage 3) were cultured in osteogenic medium (containing 5
mM β-glycerophosphate, 50 μg/ml ascorbic acid and 80 nM dexamethasone) for 11 (early
OBs; ALP activity), 14 (pre-OBs) or 21 days (mature OBs; matrix mineralization). ALP
activity was quantified by hydrolysis of p-nitrophenylphosphate into p-nitrophenol (Sigma-
Aldrich) and mineralization assessed by alizarin red staining.
Real-time reverse transcription-PCR analysis
TaqMan Gene Expression Assays (Applied Biosystems, Foster City, CA, USA) were
performed according to manufacturer’s instructions. Assay IDs were: Runx2,
Hs01047976_m1, Osterix, Hs00541729_m1, Osteopontin, Hs00959010_m1, Osteocalcin,
Hs01587814_g1, DKK-1, Hs00183740_m1, Osteoprotegerin, Hs00900358_m1, RANKL,
Hs00243522_m1_ and IRE1α, Hs00176385_m1. Relative quantification of the target gene
expression was calculated by the comparative threshold cycle method. Samples were
performed in duplicate with GAPDH used for normalization.
Reporter Assay
MC3T3-E1 murine pre-OB cells were transfected with Cignal Finder dual-luciferase
reporter constructs (SABiosciences, Valencia, CA, USA) using X-tremeGENE HP reagent
(Roche, Indianapolis, IN, USA). Twenty-four hours after transfection, cells were drug
treated for 24 h in OptiMEM (Invitrogen) containing 1% fetal bovine serum and assayed
using the Dual-Glo Luciferase Assay System (Promega, Madison, WI, USA). As the CMV
promoter driving the Renilla reporter construct used for normalization was modulated itself
by PIs, firefly luciferase activity is presented as a ratio over the average of vehicle group.
The assay was repeated twice with six replicates per condition to partially account for the
lack of normalization.
Western blot
Protein isolation and western blot analyses were performed as in Garcia-Gomez et al.33
using antibodies against IRE1α (Cell Signaling Technology, Danvers, MA, USA) and α-
tubulin (Calbiochem, Damstadt, Germany).
Gene silencing
hMSC-TERT cells were transfected with either ON-TARGETplus SMARTpool siRNA
targeting human IRE1 or ON-TARGETplus non-targeting pool as negative control
(Dharmacon, Lafayette, CO, USA), using SAFEctin-STEM (Deliverics, Edinburg, UK)
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following supplierś instructions. Minimal toxicity of transfection reagent allowed repeated
siRNA transfections (three times per week for 3 weeks).
In vivo drug treatment
PIs were administered to mice on the following weekly schedules: bortezomib (1 mg/kg
intravenously days 1 and 4); carfilzomib (5 mg/kg for C57Bl/6, 3 mg/kg for KaLwRij,
intravenously days 1 and 2); oprozomib (30 mg/kg by oral gavage once daily for 5
consecutive days followed by 2 days of rest). Vehicle mice were administered both oral 1%
carboxy-methylcellulose (oprozomib schedule) and intravenous 10% Captisol in 10 mM
citrate buffer, pH 3.5 (carfilzomib schedule). In Figure 5f, following 14 days of drug
treatment, three doses of 1 mg/kg of RANKL were given intraperitoneally at 24 h intervals
as described in Tomimori et al.34 Serum was collected 90 min after the final RANKL
injection.
Micro-computed tomography (microCT)
Tibial metaphyses were scanned with a microCT-40 system (Scanco Medical, Wayne, PA,
USA) as described previously.35 A three-dimensional cubical voxel model of bone was built
and calculations were made for relative bone volume per total volume and trabecular
number.
Bone turnover markers
Carboxy-terminal telopeptide collagen crosslinks (CTX) and N-terminal propeptide of type I
procollagen (P1NP) were measured in fasting serum using ELISA systems
(Immunodiagnostic Systems, Scottsdale, AZ, USA).
In vivo bone formation rate
Mice were injected with 20 mg/kg calcein (Sigma-Aldrich) in 2% sodium bicarbonate 7
days and 2 days prior to sacrifice. Bone formation rate (BFR/BS) in femoral trabeculae was
calculated as previously described36 using Bioquant Osteo software (Bioquant, Nashville,
TN, USA).
Mouse models of BM disseminated MM
A total of 1 × 106 murine 5TGM1-GFP cells were injected intravenously into 8-week-old
female KaLwRij mice.32 Clonal tumor expansion was monitored by serum murine IgG2b
ELISA (Bethyl Laboratories, Montgomery, TX, USA). Drug treatment was initiated 14 days
following tumor injection. At sacrifice, GFP + tumor burden was assessed by flow
cytometry. In separate experiments, 2 × 106 human RPMI-8226-luc were injected
intravenously into NOD-SCID-IL2Rγ−/− mice and tumor development was monitored by
non-invasive bioluminescence imaging with an IVIS 100 system (Caliper, Hopkinton, MA,
USA; exposure time 300 s, binning 16, field of view 12, f/stop 1, open filter) following
intraperitoneal injection of 150 μg/g D-luciferin (Biosynth, Naperville, IL, USA).37 Serum
human Igλ was measured by ELISA (Bethyl Laboratories).
Statistical analyses
Assays were performed at least three times using cells from at least three different
individuals and duplicates (reverse transcription-PCR) or triplicates were measured.
Statistical comparisons were performed on in vitro experiments (Figures 1 and 4) using the
non-parametric Mann–Whitney U test (2 groups) and Kruskal–Wallis with Mann–Whitney
U post-hoc test with Bonferroni’s adjustment (≥3 groups); in vivo studies (Figures 5 and 7)
used the Student’s t-test (2 groups) or one-way ANOVA with Tukey’s multiple comparison
test (≥3 groups): *P<0.05; **P<0.01; ***P<0.001.
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RESULTS
Continuous or physiologic transient administration of carfilzomib or oprozomib is cytotoxic
to human MM cells in vitro Under 48 h of continual drug incubation, carfilzomib and
oprozomib exerted a cytotoxic effect on a panel of 10 human MM cell lines similar to
bortezomib. In agreement with previous reports, the IC50 was approximately 2 nM for
bortezomib, 3 nM for carfilzomib22 and 25 nM for oprozomib27 (Figure 1a). However,
pharmacokinetic data indicate that in vivo exposure to drug is approximately 4 h following
oral delivery of oprozomib28 and approximately 1 h with intravenous administration of
carfilzomib or bortezomib.22,38 To more accurately replicate this physiological situation in
vitro, cells were transiently treated with oprozomib for 4 h and with carfilzomib or
bortezomib for 1 h followed by an additional 48 h culture in drug-free media. Myeloma cell
lines remained susceptible to proteasome inhibition under short treatment conditions (Figure
1b), although increased doses were required to achieve similar efficacy (8 nM bortezomib, 6
nM carfilzomib and 50 nM oprozomib). Effective transient doses were still well below the
maximum serum levels (Cmax) attained in patients (bortezomib: 0.162 μM (1.3 mg/m2
intravenous)39; carfilzomib: 0.95 μM (20 mg/m2 intravenous);40 oprozomib: 3.8 μM (30 mg
per os)28). The decrease in MM viability by carfilzomib and oprozomib was attributed to
both inhibition of proliferation and apoptosis induction (data not shown), consistent with
previous reports examining these PIs.21,27
Cells within the BM microenvironment, specifically BMSCs and OCs, produce factors that
support the growth and survival of myeloma cells1 while protecting them from
chemotherapy-induced apoptosis.41 Under experimental settings resembling the protective
environment of bone, all PIs remained effective at inhibiting MM.1S survival, although co-
culture with human MM BMSCs (Figure 1c) or OCs (Figure 1d) required approximately
twofold dose increases to reach similar cyto-toxic efficacy (Figure 1c). Notably, the required
doses remained well within the range achievable in vivo.28,39,40 In summary, similarly to
bortezomib, carfilzomib and oprozomib exert potent cytotoxic effects on myeloma cells
under continuous and physiological dosing conditions, even in the presence of protective
BMSCs and OCs.
Oprozomib and carfilzomib inhibit OC differentiation and function in vitro
Similar to bortezomib, carfilzomib and oprozomib strongly inhibited the in vitro
differentiation and formation of mature, multinucleated OCs of human (Figure 2a) and
murine (Supplementary Figure 1A) origin. Under continuous treatment, osteoclastogenesis
was abrogated by 50% at concentrations similar to doses exerting myeloma cell cytotoxicity
(bortezomib =1.21 nM, carfilzomib = 2.43 nM; oprozomib = 25.88 nM). Importantly, this
inhibitory effect was evident under both continuous and physiological transient drug
treatment conditions, though transient treatment required approximately fivefold higher
doses. Notably, oprozomib and carfilzomib did not exert cytotoxic effects on OCs, as cell
densities in cultures for IC50 doses were not markedly reduced (Figure 2a and
Supplementary Figure 1A). Murine macrophages (OC progenitors) were also resistant to the
cytotoxic effects of PIs, with IC50’s greater than 1 μM, approximately 50–100-fold higher
than doses required to kill myeloma cells (Supplementary Figures 1B and C). Thus, under
physiological conditions and at concentrations cytotoxic to myeloma cells, carfilzomib and
oprozomib inhibited OC differentiation without exerting cytotoxic effects on their precursor
cells.
To test the ability of the new PIs to inhibit osteoclastic bone resorption, OC cultures from
human PBMCs were established on calcium substrate-coated slides. Similarly to
bortezomib,17,18,42 a dose-dependent reduction in resorption pit area was observed
following continuous incubation with carfilzomib or oprozomib (Figure 2b). The
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concentration of each drug required to inhibit resorption was less than that required to
inhibit OC differentiation, most notably for oprozomib (Figures 2a and b, left), suggesting
that these PIs may independently affect OC resorptive function. Both preservation of the F-
actin ring and expression of the αVβ3 integrin are necessary for maintenance of OC
structural polarization, adhesion to bone matrix and formation of a sealing zone for effective
bone resorption.43,44 Treatment with all PIs resulted in a partial or complete disruption of
the F-actin ring (Figure 2c) and reduced expression of αVβ3 integrin (Supplementary Table
1). OC-mediated resorption also requires functional signaling through a complex pathway
involving mitogen-activated protein kinase (MAPK) and NF-κB45. PI treatment of human
pre-OCs prevented RANKL-induced NF-κB activation, with the p65 subunit being retained
in the cytoplasm (Figure 2d). This effect is consistent with impaired proteasomal
degradation of I-κB, suggesting that, similar to bortezomib,17,18 carfilzomib and oprozomib-
mediated inhibition of ex vivo OC activity may partially act through disruption of RANKL-
induced NF-κB signaling. Together, these data demonstrate that epoxyketone-based PIs are
capable of inhibiting OC resorptive function through multiple mechanisms.
Carfilzomib and oprozomib promote osteogenic differentiation and mineralization in vitro
While the inhibition of pathological bone resorption through anti-catabolic agents is
inarguably crucial for the control of myeloma bone disease, anabolic treatments capable of
stimulating new bone formation are important for reversing damage. As several PIs
including bortezomib13–16 and epoxomicin29 are recognized to enhance OB formation and
function, we tested whether the same held true for carfilzomib and oprozomib. Murine
mesenchymal stem cells (MSC), the OB progenitors, were resistant to cytotoxic effects
(Supplementary Figure 2A) and alterations in proliferation (Supplementary Figure 2B) at
clinically relevant doses of PIs. When differentiating primary human MM patient MSCs
(Figure 3a) or murine MSCs (Supplementary Figure 2C) into OBs in vitro, carfilzomib and
oprozomib increased matrix mineralization and calcium deposition under both continuous
(days 0–21) and transient (1–4 h dose on day 0) dosing conditions. Furthermore, both drugs
dose-dependently increased ALP activity, a surrogate marker of early osteoblastic
activation, in human myeloma patient OBs (Figure 3b). Increased ALP activity and
mineralization were also observed when treating MSCs from healthy donors (data not
shown), suggesting that such effects are not isolated to myelomatous stroma. Likewise,
markers of OB differentiation were significantly elevated in PI-treated OBs derived from the
hMSC-TERT cell line compared with vehicle-treated controls (Figure 3c). Of note, at
equimolar concentrations, carfilzomib induced a significantly higher expression of Osterix
and osteo-pontin as compared with bortezomib. In addition, all PIs induced modest but
significant reductions in mRNA levels of the OB inhibitory protein Dkk-1 in pre-OBs
(Figure 3c).
In reporter assay systems, 24 h treatment of MC3T3-E1 osteoprogenitor cells with PIs
enhanced the activity of Smad2/3/4, serum response element (SRE) and AP1 transcription
factors (Figure 4a). Although transforming growth factor β signaling exerts inhibitory effects
in mature OBs,46 activity of Smad2/3 together with Smad4 promotes early osteoprogenitor
commitment and differentiation by inducing OB-specific gene transcription.47 Likewise,
MAPK signaling cascades through ERK (extracellular-signal-regulated kinase) (SRE) and
JNK (c-Jun N-terminal kinase) (AP1) have been reported to upregulate Runx2 and Osterix,
supporting osteogenic differentiation.48,49 Conversely, the activation of the unfolded protein
response (UPR) is of particular importance in cells specialized to secrete proteins, such as
plasma cells, endocrine cells and OBs. The IRE1-XBP1 pathway has been recently shown to
promote OB differentiation by driving transcription of Osterix.50 Treatment of hMSC-TERT
cells with carfilzomib or oprozomib resulted in upregulation of the IRE1α component of the
UPR (Figure 4b). IRE1α inhibition by siRNA significantly diminished PI-enhanced
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mineralization (Figures 4c and d), underscoring the crucial role of IRE1α in the promotion
of OB activity by PIs. In MM, osteoclastogenesis and OC activity is partially modulated by
OB expression of membrane-bound RANKL and secreted osteoprote-gerin.1 The presence
of PIs during OB differentiation inhibited RANKL expression, yet only a modest trend
toward increase of osteoprotegerin mRNA levels was observed (Figure 4e). In summary, PIs
directly stimulated the transforming growth factor β and MAPK pathways and increased the
activity of the UPR resulting in enhanced OB differentiation and matrix mineralization,
while indirectly hindering OC stimulation through decreased OB expression of RANKL.
Epoxyketone-based PIs exert bone anabolic effects on non-tumor bearing mice
In vitro evidence suggests that PIs exert cell-autonomous effects on both OCs and OBs. To
examine their effects on non-myelomatous bone, PIs were administered to non-tumor
bearing immunocompetent C57Bl/6 mice for two weeks. Similar to bortezomib, treatment
with carfilzomib or oprozomib increased trabecular bone parameters (Figures 5a and b). All
three PIs comparably inhibited OC function as measured by decreased serum levels of
collagen breakdown products (carboxy-terminal telopeptide collagen crosslinks) resulting
from bone resorption (Figure 5c). Furthermore, all drugs significantly increased OB activity
as measured by increased serum levels of N-terminal propeptide of type I procollagen, a
marker of bone formation, compared with controls (Figure 5d). Notably, carfilzomib exerted
an increase in N-terminal propeptide of type I procollagen that was significantly greater than
that obtained with bortezomib. In agreement, double calcein labeling demonstrated that PIs
increased bone formation rate (Figure 5e). These data demonstrate that the epoxyketone-
based PIs carfilzomib and oprozomib enhance bone volume in healthy mice through both
anabolic and anti-catabolic properties that are equipotent to or even superior to that of
bortezomib.
Following treatment with anti-cancer agents, it is difficult to discern whether protection
from tumor-associated bone loss is due to direct effects on bone cells or indirectly to a
decrease in overall tumor burden. To examine the efficacy of PIs in decreasing pathological
OC activation without the confounding factor of tumor burden, in vivo injection of RANKL
(three doses over 50 h34) was used to mimic OC stimulation by myeloma cell-derived
RANKL. We found that all PIs prevented a RANKL-induced increase in carboxy-terminal
telopeptide collagen crosslinks (Figure 5f), demonstrating that this class of compounds
exerts direct effects on the activity of pathologically activated OCs.
Carfilzomib and oprozomib decrease MM tumor burden and protect mice from bone
destruction
To examine the combined anti-tumor and bone-preserving effects of carfilzomib and
oprozomib for therapeutic treatment of established myeloma, we utilized two in vivo mouse
models. Intravenous injection of 5TGM1-GFP murine myeloma cells into
immunocompetent, syngeneic C57Bl/KaLwRij mice yields disseminated tumors with
significant bone destruction within 28 days.51,52 5TGM1 tumors were established for 14
days after which bortezomib, carfilzomib, or oprozomib were administered on schedules
correlating with each drug’s clinical dosing (see Materials and Methods). All PIs
significantly decreased tumor burden as measured by serum levels of the clonotypic
antibody IgG2b (Figure 6a) or by percentage of BM or spleen comprised of GFP-expressing
tumor cells (Figures 6b and c). Protection from tumor-induced bone loss was evident by
microCT in all PI-treated groups (Figures 6d and e), with serum markers of bone turnover
showing significant anti-resorptive (Figure 6f) and bone anabolic (Figure 6g) effects.
Notably, although differences within PIs were not statistically significant, a trend toward
increased N-terminal propeptide of type-I procollagen activity with carfilzomib and
oprozomib versus bortezomib was observed.
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Finally, the efficacy of oprozomib was examined in NOD-SCID-IL2Rγ−/− mice bearing
established human RPMI-8226-luc myeloma cells. Oprozomib treatment decreased tumor
burden as measured by bioluminescent imaging (Figure 7a) and serum levels of human Igλ
secreted by RPMI-8226-luc cells (Figure 7b). MicroCT analysis demonstrated marked
tumor-associated bone loss in vehicle-treated mice. By contrast, oprozomib-treated mice
presented significant increases in trabecular bone parameters (Figures 7c and d). Serum
markers of bone turnover showed that oprozomib inhibited bone resorption (Figure 7e)
while enhancing bone formation (Figure 7f). In summary, these data demonstrate that orally
administered oprozomib exerts in vivo anti-myeloma activity along with bone anti-catabolic
and anabolic effects in mice bearing human MM.
DISCUSSION
In this report, we have demonstrated that the next generation epoxyketone-based PIs
carfilzomib and oprozomib exerted potent anti-myeloma growth effects, inhibited
osteoclastogenesis, and resorption, and enhanced OB formation and function in vitro under
clinically relevant doses and exposure periods. Consistently, these PIs decreased bone
resorption and increased bone formation in non-tumor bearing mice while decreasing tumor
growth and pathologic bone loss in models of BM-disseminated myeloma. Notably, in both
in vitro and in vivo models, carfilzomib consistently appeared to enhance OB activity to a
greater extent than bortezomib (Figures 3c, 5d and 6f), suggesting that this compound may
offer an additional benefit to patients by enhancing the extent to which lost bone can be
rebuilt.
These data also demonstrate that proteasome inhibition with the orally bioavailable
compound, oprozomib, has similar efficacy to intravenously delivered PIs. Although effects
were achieved at higher concentrations, pharmacokinetic data demonstrate that
concentrations well surpassing these doses are readily obtained following oral dosing of
oprozomib.28,40 Importantly, peptide epoxyketones such as carfilzomib and oprozomib,
specifically inhibit N-terminal threonine active proteasome subunits in contrast to dipeptide
boronates that can also inhibit serine proteases. This difference may account for the
favorable toxicity profiles and relatively low rates of peripheral neuropathy associated with
epoxyketone PIs.24,53 This could permit more prolonged and intense dosing regimens,
potentially increasing the efficacy of the drug. Bortezomib is dosed on a day 1, day 4
schedule, allowing for full recovery of proteasome activity between doses.38 In ongoing
clinical trials, carfilzomib is dosed intravenously on two subsequent days; experimental
evidence suggests that daily dosing is similarly well tolerated, although the necessity for
intravenous delivery limits this use in practice.22,24,25 In current trials, oprozomib is dosed
orally on five continuous days. While we demonstrate that single in vitro pulse treatments of
oprozomib effectively exert anti-tumor, anti-OC, and pro-OB effects, the QDx5 repeated
dosing schedule increases the overall period during which proteasome activity is inhibited.
Therefore, the continuous treatment of cell cultures in vitro may more closely mimic the in
vivo activity of oprozomib under this regimen. Furthermore, we have observed these effects
below the maximal tolerated dose of oprozomib, reported to exceed 50 mg/kg.27
The BM microenvironment supports MM cell growth and certain drugs are unable to
overcome this protection.54 In addition to their direct effects on tumor cell survival, PIs also
exert indirect anti-tumor effects by rendering the host microenvironment less hospitable. In
agreement with data in Waldenstrom’s macroglobulinemia,55 we found that both
carfilzomib and oprozomib remained cytotoxic to MM cells co-cultured with BMSCs or
OCs. Furthermore, tumor-produced factors can unbalance normal bone turnover resulting in
pathological osteolysis, which in turn further stimulates tumor growth.45 Shifting the bone
microenvironment to an anabolic or bone-building state, would then negatively impact
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myeloma progression.3 Comparably to bortezomib and other PIs, our data demonstrate that
oprozomib and carfilzomib exert direct effects on OCs in part through disruption of
RANKL-induced NF-κB signaling,17,18,30,56 together with reduced expression of integrin
αVβ3 and F-actin ring disruption.30,42 Carfilzomib and oprozomib also modulate OB
differentiation and function in vitro similarly to bortezomib,14–16 augmenting bone
formation marker expression and increasing ALP activity and bone nodule formation. We
have identified the UPR as a novel pathway impacted by PIs that results in enhanced
osteoblastogenesis. This is of particular interest as induction of a pro-apoptotic UPR has
been shown to be a mechanism by which PIs induce cytoxicity in myeloma cells.57,58 Thus,
agents inducing the UPR may prove beneficial in myeloma owing to both direct anti-
tumor59 and OB-stimulatory effects, similar to PIs. In differentiating OBs, bortezomib,42
carfilzomib and oprozomib also reduced RANKL expression, therefore diminishing their
OC stimulating ability. Other groups have reported that oprozomib may block migration of
MM to the bone and decrease angiogenesis.27 Of note, epoxyketone-based PIs also
modulated OC and OB activity in non-tumor bearing mice, suggesting that they may be
equally effective as an adjuvant therapy in other pathologic bone diseases, including
rheumatoid arthritis and osteoporosis.
In summary, the next generation PIs carfilzomib and oprozomib are effective at decreasing
both myeloma growth and myeloma-associated bone disease by: (i) direct killing of
myeloma cells; (ii) inhibition of OC differentiation and resorption; and (iii) enhancement of
OB formation and function. As these drugs progress through clinical trials, prospective
studies of bone turnover markers, bone mineral density and documentation of skeletal events
would be of particular value to determine whether these new PIs obtain meaningful
combined benefits on myeloma and associated bone disease.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Continuous or physiologic transient administration of carfilzomib or oprozomib is cytotoxic
to human MM cells in vitro. (a) A panel of 10/human MM cell lines were treated with the
indicated doses of bortezomib, carfilzomib or oprozomib continuously for 48 h and
subjected to MTT assay for viability. (b) MM cell lines were treated with indicated drug
doses on day 0 for 1 h (bortezomib, carfilzomib) or 4 h (oprozomib). Cells were then
washed and cultured in drug-free media for 48 additional h and viability assessed by MTT
assay. (c, d) PIs overcome the proliferative and protective effects of bone microenvironment
cells. MM.1S cells labeled with firefly luciferase (MM.1S-luc) were cultured in the presence
(filled bars) or absence (open bars) of human (c) CD138− BMSCs or (d) OCs. Cultures were
treated with indicated doses of drugs for 48 h (BMSC) or 5 days (OC) and MM cell viability
readout by luciferase activity. Results are expressed as mean±s.d. RLU, relative
luminescence units.
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Figure 2.
Oprozomib and carfilzomib inhibit OC differentiation and function in vitro. (a) Human OCs
were generated from PBMCs cultured in osteoclastogenic medium for 21 days in the
presence or absence of indicated concentrations of the PIs (continuous treatment, left panel);
alternatively, PIs were present only for the initial 4 h of differentiation (transient treatment,
right panel). OCs were identified as multinucleated (≥3 nuclei) TRAP + cells.
Representative micrographs of differentiated OCs after transient treatment are shown. (b) To
assess inhibition of mineralized matrix resorption, PBMCs were seeded on calcium-coated
slides and maintained in osteoclastogenic medium for 17 days with or without indicated
concentrations of the drugs. Graphs represent mean values of samples from OCs derived
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from three healthy donors±s.d. *P<0.05 between treated cultures and vehicle control. Bar
=50 μm. (c) PIs disrupted the integrity of the actin ring in multinucleated pre-OCs (14 days
in osteoclastogenic medium under continuous PI-treatment). Actin =phalloidin–rhodamine,
DAPI =nuclei; representative micrographs are reported. Bar =50 μm. (d) Pre-OCs were
treated with indicated concentrations of PIs for 3 h prior to stimulation with RANKL for 30
min. In absence of PIs (vehicle), RANKL induces p65 translocation to the nucleus, whereas
in PI-treated cells the p65 subunit of NF-κB is retained in the cytoplasm. p65 subunit
=visualized in red, DAPI =nuclei; representative micrographs for each PI are shown (Bar
=12.5 μm).
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Figure 3.
PIs promote osteogenic differentiation and mineralization in vitro. (a) Primary MSCs from
MM patients (6/9 with osteolytic lesions) were cultured in osteogenic medium either in the
continuous presence of PIs (left panel) or transiently treated on day 0 for 4 h (right panel).
Mineralization was analyzed by alizarin red staining and subsequent dye quantification in
OBs differentiated for 21 days; representative images of alizarin red staining following
transient treatment are shown. Results are expressed as the mean±s.d. (b) In the presence of
PIs and at day 11 of osteogenic differentiation, ALP activity was measured in OBs derived
from MSCs from five MM patients (3/5 with osteolytic lesions). Graphs illustrate mean
values±s.e.m. (c) Total RNA from the hMSC-TERT cell line was isolated at day 14 of
differentiation in the presence of PIs at indicated doses, and expression of osteogenic-related
markers (Osterix, osteopontin, osteocalcin) and DKK-1 were evaluated using real-time
reverse transcription-PCR. Expression levels for each gene were normalized with respect to
GAPDH expression and referred to vehicle control. Data are represented as the mean±s.d.
from three different experiments. In all panels: *P<0.05, versus vehicle control or between
indicated groups.
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Figure 4.
PI treatment diminishes RANKL expression in OBs and promotes osteogenic differentiation
and function through activation of the transforming growth factor β (TGFβ), MAPK and
UPR pathways. (a) Reporter assays demonstrated that the activity of the Smad2/3/4, MAPK/
ERK (serum response element; SRE) and MAPK/JNK (AP1) pathways were increased in
MC3T3-E1 OB-progenitor cells following 24 h of continuous treatment with PIs; results are
expressed as mean±s.e.m. (b) Western blot for the IRE1α component of the UPR in hMSC-
TERT cells treated with PIs for 24 h (25 nM bortezomib and carfilzomib, 250 nM
oprozomib). Brefeldin A (600 ng/ml) was used as a positive control. (c) Expression of
IRE1α was reduced at the mRNA and protein levels 48 h after transfection with IRE1
targeting siRNAs. (d) The hMSC-TERT cell line was maintained for 14 days in osteogenic
medium with PIs (5 nM bortezomib/carfilzomib or 25 nM oprozomib) and transfected 3
times/week with IRE1 targeting or non-targeting (NC) siRNAs. Mineralization was greatly
reduced when IRE1α was silenced even in the presence of PIs. (e) The hMSC-TERT cell
line was maintained in osteogenic medium for 21 days in the presence of PIs and expression
of RANKL and osteoprotegerin was assessed by real-time reverse transcription-PCR.
Maximal effect on the relative expression of RANKL (day 14) or osteoprotegerin (day 7) is
shown; results are expressed as mean±s.d. In all panels: *P<0.05, **P<0.01, ***P<0.001
versus vehicle or between indicated groups.
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Figure 5.
Epoxyketone-based PIs exert bone anabolic effects on non-tumor bearing mice. C57Bl/6
mice (n =10/group) were treated for 2 weeks with vehicle, bortezomib, carfilzomib or
oprozomib on dosing schedules outlined in Materials and Methods. (a, b) MicroCT analyses
show that all PIs induced an equivalent increase in trabecular bone volume and number. (c)
Bone resorption (serum carboxy-terminal telopeptide collagen crosslinks (serum CTX)) was
significantly and equivalently decreased with each PI. (d) OB function (serum N-terminal
propeptide of type I procollagen (serum P1NP)) was significantly increased in all PI-treated
animals compared with vehicle-treated. Notably, P1NP levels in carfilzomib-treated mice
were significantly greater than those of bortezomib-treated mice. (e) Trabecular bone
formation rate was measured by double calcein labeling; calcein incorporates into actively
mineralizing bone with the distance between labels being proportional to the amount of
newly formed bone within the 5-day interlabel period. PI treatment increased the bone
formation rate per bone surface (BFR/BS) as assessed by dynamic histomorphometry (Bar
=10 μm). (f) PIs inhibited RANKL-induced pathological bone resorption in the absence of
tumor. After 2 weeks of PI treatment as above, mice were given three doses of purified
RANKL (n =5/drug) or PBS vehicle (n =5) to stimulate OC activity. Serum CTX measured
90 min following the final RANKL dose is expressed as a percent of the same mouse prior
to RANKL stimulation. All results are expressed as mean±s.e.m. *P<0.05, **P<0.01,
***P<0.001 versus vehicle or between indicated groups.
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Figure 6.
PIs decrease myeloma burden and associated bone destruction in an immunocompetent
murine model. 5TGM1-GFP murine myeloma cells were injected into syngeneic C57Bl/
KaLwRij mice. After 14 days, mice were randomized into PI treatment groups (n≥7/group)
and dosed for an additional 2 weeks. All PIs decreased tumor burden as measured by (a)
levels of serum IgG2b (clonotype of 5TGM1 cells) and (b, c) percent of GFP + tumor cells
within the BM or spleen upon sacrifice at day 28. (d, e) MicroCT analysis demonstrated that
treatment with PIs protected animals from myeloma-induced loss of trabecular bone volume
and number. (f) Serum carboxy-terminal telopeptide collagen crosslinks (serum CTX) was
significantly decreased and (g) serum N-terminal propeptide of type I procollagen (serum
P1NP) was significantly increased in all PI-treated animals compared with vehicle-treated
animals. All results are expressed as mean±s.e.m. *P<0.05, **P<0.01, ***P<0.001 versus
vehicle or between indicated groups.
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Figure 7.
Oprozomib decreases human MM tumor burden and protects mice from bone destruction.
Immunocompromised NOD-SCID-IL2Rγ−/− mice (n =5/group) were intravenously injected
with RMPI-8226 human MM cells stably labeled with firefly luciferase. Tumors were
allowed to establish for 3 weeks after which mice were randomized into treatment groups.
During weeks 3–6 animals were treated with oprozomib (n =5) or vehicle (n =5). (a) Tumor
burden was monitored weekly by in vivo bioluminescence imaging. Mice treated with
oprozomib had decreased tumor burden compared with those in the vehicle treated group.
Representative image of hind limb tumor burden as visualized on week 6. (b) Serum human
Igλ (secreted by RPMI-8226 cells) was decreased in oprozomib-treated mice at the time of
killing, indicating decreased tumor burden. (c, d) Although tumor-associated bone loss was
evident in vehicle-treated mice, trabecular bone was preserved with oprozomib treatment as
measured by micro CT. (c) Representative 3D reconstructions. (d) Oprozomib significantly
increased trabecular bone volume and number. Oprozomib treatment decreased serum
carboxy-terminal telopeptide collagen crosslinks (serum CTX) (e) and increased serum N-
terminal propeptide of type I procollagen (serum P1NP) (f). Results are expressed as mean
±s.e.m. *P<0.05, **P<0.01.
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